FY2018 R&D Day

from the beginning

FY2018 R&D Day

Forward-Looking Statements

Toward 2025 Vision & 5-Year Business Plan

Establish Oncology Business Continuously Generate Innovative Medicine Changing SOC

R&D 2025 Vision

R&D 2025 Vision

Daiichi Sankyo Cancer Enterprise:
Deliver, Scale Up and Lead in Science

Today's Agenda

• 1 Cancer Enterprise 2025

Daiichi Sankyo Cancer Enterprise 2025

Cancer Enterprise 2025: Multiple Opportunities for 7 new drugs

CE is a Virtual Organization that Delivers

ADC Manufacturing: Meeting Massive Increase in Demand

CE is Scaling Up the Enterprise

Daiichi Sankyo | A Traditional Japanese Company Transforming into a Global Power

CE Leadership in Science

Enhanced ADC Technology

Daiichi Sankyo ADC Franchise

• 2 DS-8201

ADC | DS-8201 (fam-trastuzumab deruxtecan) Top News

Clinical Program

Clinical Program

Drug-related ILD (Interstitial lung disease)

Safety: ILD

Safety: ILD

ILD experience Breast Cancer at Recommended Dose

HER2 Positive Breast Cancer: New Data

HER2 Low Breast Cancer

HER2 Low Breast Cancer P3 Study Design

HER2 Positive Gastric Cancer

NSCLC HER2 Mutated or Expressing

CRC by HER2 Status IHC/FISH

Patient Selection & CDx Strategy

DS-8201 is Leading the Second Generation HER2 ADC Race with the Most Ongoing Trials

What Have We Learned?

• 3 U3-1402

U3-1402 (HER3 ADC): First Time in Human Safety Profile to Date (Nov. 06, 2018)

Efficacy Data in Ph 1, Breast Cancer Study

Efficacy by Dose Level in Ph 1 BC Study

NSCLC Ph 1 Study

HER3 Expression in Cancer (IHC)

Directional Development Plan

HER2 and HER3 ADCs' Overlap

• 4 Next DXd ADCs

DS-1062 TROP2 ADC | Ph 1 Study : Lean Plan to POC

B7-H3 | An Attractive Target for ADC Therapy

DS-6157 | First-in Class GPR20 ADC

• 5 Quizartinib

AML/Hematology | Steady Progress

Refractory / Relapsed FLT3-ITD AML

Highly Potent and Selective Type II Kinase Inhibitor

Clarification of the Mechanism of Action

QuANTUM-FIRST | Front-line AML

• 6 Pexidartinib

TGCT is Rare, Non-malignant Disease with Large Pool of Prevalent Patients

Proposed Indication

ENLIVEN Study Efficacy & Safety

• 7 Recap

Cancer Enterprise | Major Clinical Pipeline

Cancer Enterprise | Upcoming Milestones

Cancer Enterprise | Deliver, Scale Up, Lead

Contact address regarding this material

HER3 ADCs

TROP2 ADCs

B7-H3 ADCs

GPR20 ADCs

HER3 Protein Expression Across Cancers

TROP2 Expression in Various Cancers

B7-H3 Protein Expression in Various Cancers

Abbreviations

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8

• Q&A 9